Frontlight ResearchEarly access
Taking peoplePhase 2
TCP-25 gel for wound healing in people with epidermolysis bullosa
Tests TCP-25 gel on wounds in people with epidermolysis bullosa.
Key facts
- Who runs it
- Xinnate AB
- Where
- France, Greece, Italy, Poland, Spain, and Sweden12 sites in 6 countriesChoose a country to see its sites
- Trial code
- Registry title
- A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in Patients with Epidermolysis Bullosa
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 37 people, planned
- Started
- 23 Dec 2025
- Expected to end
- 1 Nov 2027
- Type of study
- Interventional
- Record updated
- 12 November 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Male or female patients with documented diagnosis of DEB or JEB, confirmed by genetic testing and/or by a skin biopsy with immunofluorescence mapping. • Patients ≥4 years old. Note: Initially, patients ≥12 years will be enrolled. Enrollment will be open to 4 to 11 year old pediatric patients (both inclusive), after a DMC reviews and provides a positive opinion regarding the safety and tolerability of the IMP in at least 2 patients 12 to 18 years old who have completed at least 4 weeks of IMP use and in all patients > 18years. • The patient has the presence of a well-matched index wound pair which will be included in two respective treatment areas, with a minimum distance of at least 5 cm (2 inches) between the treatment areas
Who cannot take part
- The patient has any subtype of EB other than DEB or JEB. • The patient is currently being treated or planned to be treated with systemic antibiotics. Note: Use of preventive and/or anti-inflammatory antibiotic treatment, including doxycycline, on an established treatment regimen (stable dose for ≥6 weeks before the Baseline Visit) is permitted. Use of topical antibiotics on the index wounds within 7 days before the Baseline Visit is prohibited. • Use of systemic corticosteroids >0.2 mg/kg prednisone dose equivalent per day within 30 days or use of topical corticosteroids on index wounds within 7 days before the Screening Visit. Note: Corticosteroids for inhalation, ophthalmic, or intranasal use are permitted. • The patient has a history of any of the following treatments: a. Local topical Filsuvez on the study treatment areas within 1 month before the Screening Visit, b. Local topical gene therapy with Vyjuvek on the study treatment areas within 3 months before the Screening Visit, c. Systemic mesenchymal stem cell treatment, including Ebesenar, within 6 months before the Screening Visit, or d. Cell-gene (graft) therapy, Zevaskyn, for the treatment of EB affecting the treatment areas any time before the Screening Visit
This trial has no sites in United States.
It has sites in 6 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Evaluate efficacy of TCP-25 gel in promoting wound healing and improving EB symptoms in patients with DEB or JEB Safety Objective: Evaluate safety and tolerability, including local tolerability of TCP-25 gel in patients with DEB or JEB
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in Patients with Epidermolysis Bullosa
- Plain-language title
- TCP-25 gel for wound healing in people with epidermolysis bullosaGenerated from the registry record. The registry title is the official one.
- Record updated
- 12 November 2026